Wuerstlein, R. http://orcid.org/0000-0001-7268-0840
,
Kates, R.
Gluz, O.
Grischke, E. M.
Schem, C.
Thill, M.
Hasmueller, S.
Köhler, A.
Otremba, B.
Griesinger, F.
Schindlbeck, C.
Trojan, A.
Otto, F.
Knauer, M.
Pusch, R.
Harbeck, N.
Funding for this research was provided by:
Horizon 2020 (672570)
Article History
Received: 22 November 2018
Accepted: 27 November 2018
First Online: 22 February 2019
Compliance with ethical standards
:
: Rachel Wuerstlein declares Consultant/advisory role: Agendia, Genomic Health, NanoString, Sivdon. Marc Thill declares: Consultant/advisory role: Genomic Health, Myriad. Frank Griesinger declares: Remuneration: Roche, Boehringer, BMX, MSD, Lilly, Takeda, Chugai, Celgene, Novartis, Pfizer, Abbvie, Siemens, AstraZeneca; Consultant/advisory role: Roche, Boehringer, BMX, MSD, Lilly, Takeda, Chugai, Celgene, Novartis, Pfizer, Abbvie, Siemens, AstraZeneca; Funding: Roche, Boehringer, BMX, MSD, Lilly, Takeda, Chugai, Celgene, Novartis, Pfizer, Abbvie, Siemens, AstraZeneca. Michael Knauer declares: Consultant/advisory role: Agendia. Nadia Harbeck declares: Remuneration: Genomic Health; Consultant/advisory role: Agendia. All other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.